All In Biotech

Drug Trial Radar · NCT05885464

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

A Phase 1/2, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

Last checked: Nov 19, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

5

Actual

Start

May 25, 2023

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Beam Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jun 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to \< 12 years), and a Phase 2 cohort.

Conditions

  • Lymphoblastic Lymphoma
  • T-Cell Lymphoblastic Leukemia/Lymphoma
  • Lymphoblastic Leukemia

Interventions

  • BEAM-201Biological

    A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse events (TEAEs) and treatment-related adverse events, including serious adverse events (SAEs) and dose-limiting toxicities (DLTs; in Phase 1 only)Time frame: Through study completion, an average of 25 months
  2. Overall response rate as defined as proportion of T-ALL patients achieving complete response (CR) or complete response with incomplete hematologic recovery (CRi) or T-LL patients achieving CR or PR at any point after BEAM-201 infusionTime frame: From treatment with BEAM-201 through study completion

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University School of Medicine

    Stanford, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • University of Chicago

    Chicago, Illinois

  • The University of Kansas Cancer Center

    Fairway, Kansas

  • Dana Farber and Boston Children's Hospital

    Boston, Massachusetts

  • Cleveland Clinic- Taussig Cancer Center

    Cleveland, Ohio

  • OHSU Knight Cancer Institute Hematology Oncology

    Portland, Oregon

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Sarah Cannon- TriStar Bone Marrow Transplant

    Nashville, Tennessee

  • Methodist Hospital - Texas Transplant Institute

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.